
==== Front
J Med Case Rep
J Med Case Rep
Journal of Medical Case Reports
1752-1947
BioMed Central London

39272192
4755
10.1186/s13256-024-04755-1
Case Report
A case of basal cell carcinoma of skin with bone metastasis: a case report
http://orcid.org/0000-0002-1867-1609
Khayyat Azadeh azadeh.khayyat.ak@gmail.com

1
Pour MohammadAli Esmaeil 2
Nasrollahi Hamid 3
Mehrabi Mohammad Mehdi 4
Zohouri Seyed Amir 5
Geramizadeh Bita 6
1 https://ror.org/00qqv6244 grid.30760.32 0000 0001 2111 8460 Pathology Department, Medical College of Wisconsin, 15225 W. North Ave., Apt#3, Brookfield, WI 53005 USA
2 https://ror.org/012mef835 grid.410427.4 0000 0001 2284 9329 Rheumatology Department, Augusta University at Georgia Medical Center, Augusta, GA USA
3 https://ror.org/01n3s4692 grid.412571.4 0000 0000 8819 4698 Oncology Department, Shiraz University of Medical Sciences, Fars, Iran
4 https://ror.org/01n3s4692 grid.412571.4 0000 0000 8819 4698 Plastic Surgery, Plastic, Shiraz University of Medical Sciences, Fars, Iran
5 Research Associate, Research Update Organization, Houston, TX USA
6 https://ror.org/01n3s4692 grid.412571.4 0000 0000 8819 4698 Pathology Department, Shiraz University of Medical Sciences, Fars, Iran
14 9 2024
14 9 2024
2024
18 4286 12 2023
3 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Background

Basal cell carcinoma is the most prevalent skin cancer, most characterized by local aggressiveness but with low metastatic potential, and bone metastasis is quite heterogeneous, thus the incidence profile is variable size from 0.0028% to 0.5%. We have this patient with an unusual example of basal cell carcinoma with bone metastases to add to the scarce report on this matter.

Case description

Here we document a 48-year-old Persian man with a background of being exposed to the sun for a long time. He was diagnosed with an ulcer on the cheek, which was clinically characterized and further confirmed by biopsy as morpheaform basal cell carcinoma. Following the first round of excision, multiple relapses eventually metastasized to the bone. The latter was found on follow-up radiologic scans. This case is characterized by the aggressive nature of the disease and the heterogeneity of basal cell carcinoma growth, thus challenging the conventional view of basal cell carcinoma behavior. Treatment included surgical excision of the primary lesion, which was treated with radiotherapy afterward. However, the skeleton improved slowly during follow-up, and palliative care was eventually pursued to control symptoms and improve quality of life.

Conclusions

This was a rare case of basal cell carcinoma metastasis to non-bone organs, which reminded us to consider basal cell carcinoma metastasis, especially in the case of atypical basal cell carcinoma. Therefore, risk-aware patient management is essential. Moreover, these findings highlight the role of further research into the mechanisms of basal cell carcinoma metastasis, leading to improved therapeutic strategies that may lead to potential improvements in patient outcomes.

Keywords

Sonidegib
Vismodegib
Radiotherapy
Bone metastasis
Metastatic basal cell carcinoma
issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

Basal cell carcinoma (BCC) is the most frequent nonmelanoma skin cancer, occurring primarily in the elderly, with an estimated incidence of approximately 3 million Americans per year, among all nonmelanoma skin cancers about 80%, making it a public health parable. BCC rates increased dramatically and nearly doubled from 1976–1984 to 2000–2010 [1]. There were significant interactions between family history of melanoma and number of blistering sunburns between age 15-20 years on BCC risk; similarly, sunburn reactions during either childhood or adolescence had a significant interaction with SCC risk [2]. The burden of cancer is not only medical but also financial; the annual cost of nonmelanoma skin cancer treatment in the USA is estimated at $4.8 billion. This economic crisis justifies adopting effective measures to manage this prevalent disease [3, 4]. Furthermore, although BCC usually carries a low risk of metastasis, several subtypes of BCC, including infiltrative, morphiform, micronodular, and metatypical, show an aggressive and metastatic clinical course and require early detection of malignant growth as well as treatment options. This report describes the presentation, diagnosis, and management of a patient with BCC who had extremely unusual distant bone metastases. It is the subject of BCC-causing extremely high-risk features. Further, this discussion opens to factors that contribute to BCC metastasis, including early intervention, and describes the necessity for comprehensive differential diagnosis to diagnose the metastasis early and maximize treatment and efficacy.

Case presentation

A 48-year-old Persian male patient, who was a heavy smoker with a medical history of type 2 diabetes and hypertension, but no psychiatric history or family history of cancer, presented with persistent lesions on his left cheek. He was an interested outsider exposed to ultraviolet rays. Cutaneous basal cell carcinoma (BCC) was diagnosed. Physical examination revealed a 2.0 × 1.5 × 1.2 cm mass. Initial skin histopathology showed that morpheaform BCC affects the skin and cutaneous tissues. He initially underwent surgery to remove the tumor but received no radiotherapy.

In December 2021, he visited our institution because of bone pain and wound deterioration. On admission, a large lesion measuring 8.5 × 10 cm and 5.5 cm deep was revealed on the left cheek (Fig. 1).Fig. 1 Clinical image of the patient’s ulcer, noted on presentation and measuring 8.5 × 10 cm with a depth of 5.5 cm

After consultation with an oncologist, dermatologist, and orthopedic surgeon, a bone biopsy suddenly revealed metastatic basal cell carcinoma (mBCC) in the bones, and a computed tomography (CT) scan of the face and spinal cord was three-dimensionally (3D) reconstructed and without any differentiation, including adjacent to his left maxillary sinus, especially at the left lower border defect, and lytic lesions with sclerotic borderline in the pelvic ramus. (Figs. 2, 3). The remainder of the examined area was unremarkable. Subsequent investigations, including bone scans, revealed extensive bone metastasis involving the spine, shoulders, ribs, and pelvis.Fig. 2 Computed tomography of face with 3D reconstruction and without contrast showing a defect in the left facial area adjacent to the left maxillary sinus with evidence of the defect in the left inferior border of the maxillary sinus (blue arrow)

Fig. 3 Computed tomography scan of the pelvis showing lytic lesions with sclerotic borders in pelvis bone (blue arrows)

Histologically, the primary lesion showed the strands and islands of basaloid cells embedded within a dense, sclerotic stroma. It displayed minimal cytologic atypia, and the growth pattern was highly infiltrative with hardly clear margins (Fig. 4).Fig. 4 Histopathology of the lesion at the time of bone metastasis diagnosis

The metastatic lesions of the bone showed invasive islands and strands of basaloid cells within the bone marrow. These cells disrupt the normal marrow architecture, potentially impacting hematopoiesis by replacing the marrow space.

Histologically, the bone itself may show evidence of osteolytic damage where the tumor has eroded bone tissue. This results in areas of decreased bone density, characterized by loss of normal bone trabeculae and infiltration by malignant cells. The interface between the tumor and normal bone might not be demarcated, with tumor cells invading in a diffuse pattern that makes surgical margins difficult to determine (Fig. 5).Fig. 5 Histopathology of the metastatic lesion to bone (pelvis), bone marrow penetrated by irregular clusters of malignant tumor tissue

We started palliative radiotherapy in the painful regions with palliative systemic chemotherapy consisting of cisplatin 100 mg, 5-fluorouracil 2 g, and zoledronic acid 4 mg per month. He had some symptom reduction at that time, but his left facial lesion was the same. He was still followed up in our oncology department and was clinically stable, without progression or evidence of any new lesion on cisplatin, fluorouracil, or zoledronic acid.

Discussion

As the most prevalent cancer in the USA, basal cell carcinoma is the most frequent non melanocytic skin cancer (NMSC); thus its prevalence relative to the population of all other diseases, in addition to the approximately 1 million new cases of BCC being administered in the USA yearly, warrants it as the top disease. Approximately 3000 patients die every year [5–7]. Despite its high frequency, mBCC is rare. We presented a case where cutaneous BCC metastasized to bone at a distant site. The case of such patients shall always indicate the necessity for multiple differential distinctions due to which all clinical settings must provide early detection and management to all the cases.

There has been great advancement in the management of SCC and BCC in the USA over the past 20 years, particularly in women less than 40 years of age, due to increased aging population, changes in sun exposure habits, environmental shifts, migratory patterns, and increased use of immunosuppressants [5]. BCC is normally diagnosed early and generally manageable, but there has been a marked rise in the number of reported patients of mBCC between 1981 and 2011, an indication of an increase in overall BCC cases. Wysong et al. reviewed all cases of mBCC in 2013 and updated the previous case reports [7, 8].

As the most common cancer in the USA, basal cell carcinoma is the most common NMSC, hence the highest disease in prevalence relative to the population of all the other cancers combined with approximately 1 million new cases of BCC in the USA annually. Approximately 3000 people die each year [7]. Despite its high prevalence, metastatic BCC is rare. This paper described a patient with a very rare condition: cutaneous BCC that metastasized to bone at a distant site. Such cases will always indicate having multiple differential diagnoses in clinical settings to facilitate early diagnosis and management.

While BCC is normally early detectable and manageable, there was a remarkable rise of reported mBCC cases between 1981 and 2011, indicating an overall rise in BCC cases. In 2013 Wysong et al. reviewed all cases of mBCC and updated previous reports of cases [7, 8].

A retrospective review of all MBCC cases published by Wysong et al. [7] reported 194 new cases, thereby making a total of 364 cases from 1894 to 2011. Additionally, most of the tumors are large tumors in white adult male patients, and were predominantly located in the head and neck and occurred more frequently with lymph node dissemination (Table 1). Cancer size and late treatment were important prognostic factors, and those diagnosed later had poor outcomes. Over the past three decades, 44% of patients received treatment as helpful as chemotherapy or radiation without significant improvement in survival rates. These reported data may serve as an important starting point for evaluating emerging therapies, including vismodegib and other sonic hedgehog inhibitors (sHHIs), which may offer new prospects for improving survival in patients with mBCC.Table 1 Characteristics of metastatic basal cell carcinoma cases (7)

Characteristic	Current Study (1981–2011)	Von Domarus and Stevens (1894–1980)	p-Value	
Total no. of cases	194	170		
Male, no. (%)	136 of 191 (71)	102 of 153 (67)	0.43	
Ratio (male/female)	3/1	2/1	NA	
Age at onset of primary tumor, median (range) years	50 (24–88)	45 (14–84)	0.18	
Location of primary tumor, no. (%)		
 Head and neck	122 (64)	119 (75)	0.03	
 Trunk	41 (21)	26 (17)	0.31	
 Extremities	10 (5)	11 (7)	0.65	
 Genitalia	10 (5)	2 (1)	0.04	
 Multiple sites	9 (5)	–	–	
 Interval from onset of tumor metastasis median (range) years	9 (0–30)	9 (0–45)	0.26	
 Age at first sign of metastasis, median (range) years	63 (32–92)	59 (24–89)	0.34	
Site of metastasis, no. (%)		
 Lymph node	101 (53)	63 (39)	0.01	
 Lung	62 (33)	66 (42)	0.11	
 Bone	38 (20)	44 (28)	0.12	
 Skin/subcutaneous	21 (11)	19 (12)	0.93	
 Liver	8 (4)	15 (9)	0.8	
 Time of death after diagnosis of metastasis, median (range) months	10.0 (0.5–108.0)	8.0 (1.0–192.0)	0.52	

Most basal cell carcinomas are treated with surgery, such as Mohs micrographic surgery, curettage, radiation, and chemotherapy, including cisplatin-based chemotherapy and topical therapies such as 5-FU and imiquimod. Sonic hedgehog inhibitors irrespective of the molecular signature can be used as the treatment. The findings are based on the observation of abnormalities in the hedgehog signaling system (Shh). This signaling pathway was first identified in mice in the 1990s.

Further, the hedgehog pathway is appellant to sporadic forms of BCCs and an autosomal dominant genetic disorder designed as basal cell nevus syndrome BCNS or Gorlin–Goltz syndrome. The association of developmental disorders and cyclopamine found within the California corn lily was first described in the 1960s when sheep that ate the plant produced offspring with holoprosencephaly.

It was not until the 1990s that findings confirmed that these actions resulted from the consequences of cyclopamine interacting with the endogenous transmembrane protein smoothened. PTCH, a protein that acts as a receptor in the hedgehog signaling pathway, is involved in cell communication and growth and often carries mutations in differentiated basal cell carcinomas (BCCs) and basal cell nevus syndrome (BCNS) [9–12].

New sHHIs are being examined for use in the treatment of BCC. Vismodegib was the first sound hedgehog pathway inhibitor approved by the US Food and Drug Administration in 2012 for the treatment of BCC. The understanding that dysregulated hedgehog signaling is responsible for local and metastatic BCC has led to the development of new targeted therapeutics [13, 14]. Two sonic hedgehog pathway inhibitors, vismodegib and sonidegib, have thus been approved in locally advanced and metastatic BCC treatment [15, 16].

In considering BCCs in general, and particularly when basaloid morphology is evident, the pathologist must be aware of metastatic bone lesions in their differential diagnosis. In mBCC, an early diagnosis could make all the difference in treatment efficacy and significantly improve patient survival.

Conclusions

This case report highlights the rarity of metastatic basal cell carcinoma (mBCC), suggesting the possibility of aggressive progression despite the nonmetastatic nature of BCC. We highlighted the critical importance of surveillance, as well as having vast differential diagnoses to find the metastasis earlier and start the intervention, especially with the hedgehog signaling pathway, as targeted therapies such as vismodegib and sonidegib offer potential new treatments for metastatic BCC. However, observing cases with poor prognoses despite this interventional improvement highlights the need for continued research into more effective treatment strategies.

Acknowledgements

The authors wish to thank the patient for granting permission to share his case for educational and research purposes. We also extend our gratitude to the medical and support staff who provided care and assistance during the patient’s treatment.

Author contributions

Khayyat. A, Esmaeil Pour. M.A., and Zohouri. S.A. contributed to the conception and design of the case report. Nasrollahi. H., Geramizadeh. B. and Mehrabi. M. M. were involved in patient care and data collection. Khayyat. A. gathered the data and drafted the manuscript, Khayyat. A, Esmaeil Pour. M. A., and Zohouri. S.A. critically revised it for important intellectual content. All authors read and approved the final manuscript.

Funding

No external funding was received for the preparation of this case report. All costs associated with the development and publication of this report were covered by the authors' institutions.

Availability of data and materials

Supporting data related to this case report can be made available to the corresponding author upon reasonable request, subject to patient privacy considerations.

Declarations

Ethics approval and consent to participate

The patient provided written, informed consent for the publication of this case report and any accompanying images.

Consent for publication

Written informed consent was obtained from the patient for the publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests

The authors declare that they have no competing interests concerning this case report.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Muzic JG Schmitt AR Wright AC Incidence and trends of basal cell carcinoma and cutaneous squamous cell carcinoma: a population-based study in Olmsted County, Minnesota, 2000 to 2010 Mayo Clin Proc 2017 92 890 898 10.1016/j.mayocp.2017.02.015 28522111
Muzic JG, Schmitt AR, Wright AC, et al. Incidence and trends of basal cell carcinoma and cutaneous squamous cell carcinoma: a population-based study in Olmsted County, Minnesota, 2000 to 2010. Mayo Clin Proc. 2017;92:890–8. 10.1016/j.mayocp.2017.02.015.28522111 10.1016/j.mayocp.2017.02.015
2. Wu S Han J Laden F Qureshi AA Long-term ultraviolet flux, other potential risk factors, and skin cancer risk: a cohort study Cancer Epidemiol Biomarkers Prev 2014 23 1080 1089 10.1158/1055-9965.EPI-13-0821 24876226
Wu S, Han J, Laden F, Qureshi AA. Long-term ultraviolet flux, other potential risk factors, and skin cancer risk: a cohort study. Cancer Epidemiol Biomarkers Prev. 2014;23:1080–9. 10.1158/1055-9965.EPI-13-0821.24876226 10.1158/1055-9965.EPI-13-0821
3. Wu X Elkin EE Marghoob AA Burden of basal cell carcinoma in USA Future Oncol 2015 11 2967 2974 10.2217/fon.15.180 26466906
Wu X, Elkin EE, Marghoob AA. Burden of basal cell carcinoma in USA. Future Oncol. 2015;11:2967–74. 10.2217/fon.15.180.26466906 10.2217/fon.15.180
4. Guy GP Jr Machlin SR Ekwueme DU Yabroff KR Prevalence and costs of skin cancer treatment in the U.S., 2002–2006 and 2007–2011 Am J Prev Med. 2015 48 183 187 10.1016/j.amepre.2014.08.036 25442229
Guy GP Jr, Machlin SR, Ekwueme DU, Yabroff KR. Prevalence and costs of skin cancer treatment in the U.S., 2002–2006 and 2007–2011. Am J Prev Med. 2015;48:183–7. 10.1016/j.amepre.2014.08.036.25442229 10.1016/j.amepre.2014.08.036
5. Wu TP Stein JA Nonmelanoma skin cancer in young women J Drugs Dermatol 2013 12 568 572 23652953
Wu TP, Stein JA. Nonmelanoma skin cancer in young women. J Drugs Dermatol. 2013;12:568–72.23652953
6. Gould A Missailidis S Targeting the hedgehog pathway: the development of cyclopamine and the development of anti-cancer drugs targeting the hedgehog pathway Mini Rev Med Chem 2011 11 200 213 10.2174/138955711795049871 21222574
Gould A, Missailidis S. Targeting the hedgehog pathway: the development of cyclopamine and the development of anti-cancer drugs targeting the hedgehog pathway. Mini Rev Med Chem. 2011;11:200–13. 10.2174/138955711795049871.21222574 10.2174/138955711795049871
7. Wysong A Aasi SZ Tang JY Update on metastatic basal cell carcinoma: a summary of published cases from 1981 through 2011 JAMA Dermatol 2013 149 615 616 10.1001/jamadermatol.2013.3064 23677097
Wysong A, Aasi SZ, Tang JY. Update on metastatic basal cell carcinoma: a summary of published cases from 1981 through 2011. JAMA Dermatol. 2013;149:615–6. 10.1001/jamadermatol.2013.3064.23677097 10.1001/jamadermatol.2013.3064
8. von Domarus H Stevens PJ Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature J Am Acad Dermatol. 1984 10 1043 1060 10.1016/s0190-9622(84)80334-5 6736323
von Domarus H, Stevens PJ. Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature. J Am Acad Dermatol. 1984;10:1043–60. 10.1016/s0190-9622(84)80334-5.6736323 10.1016/s0190-9622(84)80334-5
9. Keeler RF Binns W Teratogenic compounds of Veratrum californicum (Durand). V. Comparison of cyclopian effects of steroidal alkaloids from the plant and structurally related compounds from other sources Teratology 1968 1 5 10 10.1002/tera.1420010103 5696817
Keeler RF, Binns W. Teratogenic compounds of Veratrum californicum (Durand). V. Comparison of cyclopian effects of steroidal alkaloids from the plant and structurally related compounds from other sources. Teratology. 1968;1:5–10. 10.1002/tera.1420010103.5696817 10.1002/tera.1420010103
10. Chen JK Taipale J Cooper MK Beachy PA Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened Genes Dev 2002 1 2743 2748 10.1101/gad.1025302
Chen JK, Taipale J, Cooper MK, Beachy PA. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev. 2002;1:2743–8. 10.1101/gad.1025302.10.1101/gad.1025302
11. Wollina U Tchernev G Advanced basal cell carcinoma Wien Med Wochenschr 2013 163 347 353 10.1007/s10354-013-0193-5 23589318
Wollina U, Tchernev G. Advanced basal cell carcinoma. Wien Med Wochenschr. 2013;163:347–53. 10.1007/s10354-013-0193-5.23589318 10.1007/s10354-013-0193-5
12. Epstein EH Basal cell carcinomas: attack of the hedgehog Nat Rev Cancer 2008 8 743 754 10.1038/nrc2503 18813320
Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008;8:743–54. 10.1038/nrc2503.18813320 10.1038/nrc2503
13. Bakshi A Chaudhary SC Rana M Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond Mol Carcinog 2017 56 2543 2557 10.1002/mc.22690 28574612
Bakshi A, Chaudhary SC, Rana M, et al. Basal cell carcinoma pathogenesis and therapy involving hedgehog signaling and beyond. Mol Carcinog. 2017;56:2543–57. 10.1002/mc.22690.28574612 10.1002/mc.22690
14. Ross JS Gay LG Mihm MC Deep sequencing of metastatic cutaneous basal cell and squamous cell carcinomas to reveal distinctive genomic profiles and new routes to targeted therapies J Clin Oncol 2016 34 9522 9522 10.1200/JCO.2016.34.15_SUPPL.9522
Ross JS, Gay LG, Mihm MC, et al. Deep sequencing of metastatic cutaneous basal cell and squamous cell carcinomas to reveal distinctive genomic profiles and new routes to targeted therapies. J Clin Oncol. 2016;34:9522–9522. 10.1200/JCO.2016.34.15_SUPPL.9522.10.1200/JCO.2016.34.15_SUPPL.9522
15. Lear JT Oral hedgehog-pathway inhibitors for basal-cell carcinoma N Engl J Med 2012 7 2225 2226 10.1056/NEJMe1202170
Lear JT. Oral hedgehog-pathway inhibitors for basal-cell carcinoma. N Engl J Med. 2012;7:2225–6. 10.1056/NEJMe1202170.10.1056/NEJMe1202170
16. Sekulic A Migden MR Oro AE Efficacy and safety of vismodegib in advanced basal-cell carcinoma N Engl J Med 2012 7 2171 2179 10.1056/NEJMoa1113713
Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;7:2171–9. 10.1056/NEJMoa1113713.10.1056/NEJMoa1113713
